Cargando…
Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit?
PURPOSE: Incomplete reperfusion after mechanical thrombectomy (MT) is associated with a poor outcome. Rescue therapy would potentially benefit some patients with an expanded treatment in cerebral ischemia score (eTICI) 2b50/2b67 reperfusion but also harbors increased risks. The relative benefits of...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424153/ https://www.ncbi.nlm.nih.gov/pubmed/34989817 http://dx.doi.org/10.1007/s00062-021-01131-0 |
_version_ | 1784778178125889536 |
---|---|
author | Kurmann, Christoph C. Mujanovic, Adnan Piechowiak, Eike I. Dobrocky, Tomas Zibold, Felix Beyeler, Morin Vynckier, Jan Seiffge, David Meinel, Thomas R. Mordasini, Pasquale Arnold, Marcel Fischer, Urs Gralla, Jan Kaesmacher, Johannes |
author_facet | Kurmann, Christoph C. Mujanovic, Adnan Piechowiak, Eike I. Dobrocky, Tomas Zibold, Felix Beyeler, Morin Vynckier, Jan Seiffge, David Meinel, Thomas R. Mordasini, Pasquale Arnold, Marcel Fischer, Urs Gralla, Jan Kaesmacher, Johannes |
author_sort | Kurmann, Christoph C. |
collection | PubMed |
description | PURPOSE: Incomplete reperfusion after mechanical thrombectomy (MT) is associated with a poor outcome. Rescue therapy would potentially benefit some patients with an expanded treatment in cerebral ischemia score (eTICI) 2b50/2b67 reperfusion but also harbors increased risks. The relative benefits of eTICI 2c/3 over eTICI 2b50/67 in clinically important subpopulations were analyzed. METHODS: Retrospective analysis of our institutional database for all patients with occlusion of the intracranial internal carotid artery (ICA) or the M1/M2 segment undergoing MT and final reperfusion of ≥eTICI 2b50 (903 patients). The heterogeneity in subgroups of different time metrics, age, National Institutes of Health Stroke Scale (NIHSS), number of retrieval attempts, Alberta Stroke Programme Early CT Score (ASPECTS) and site of occlusion using interaction terms (p(i)) was analyzed. RESULTS: The presence of eTICI 2c/3 was associated with better outcomes in most subgroups. Time metrics showed no interaction of eTICI 2c/3 over eTICI 2b50/2b67 and clinical outcomes (onset to reperfusion p(i) = 0.77, puncture to reperfusion p(i) = 0.65, onset to puncture p(i) = 0.63). An eTICI 2c/3 had less consistent association with mRS ≤2 in older patients (>82 years, p(i) = 0.038) and patients with either lower NIHSS (≤9) or very high NIHSS (>19, p(i) = 0.01). Regarding occlusion sites, the beneficial effect of eTICI 2c/3 was absent for occlusions in the M2 segments (aOR 0.73, 95% confidence interval [CI] 0.33–1.59, p(i) = 0.018). CONCLUSION: Beneficial effect of eTICI 2c/3 over eTICI 2b50/2b67 only decreased in older patients, M2-occlusions and patients with either low or very high NIHSS. Improving eTICI 2b50/2b67 to eTICI 2c/3 in those subgroups may be more often futile. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00062-021-01131-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-9424153 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-94241532022-08-31 Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit? Kurmann, Christoph C. Mujanovic, Adnan Piechowiak, Eike I. Dobrocky, Tomas Zibold, Felix Beyeler, Morin Vynckier, Jan Seiffge, David Meinel, Thomas R. Mordasini, Pasquale Arnold, Marcel Fischer, Urs Gralla, Jan Kaesmacher, Johannes Clin Neuroradiol Original Article PURPOSE: Incomplete reperfusion after mechanical thrombectomy (MT) is associated with a poor outcome. Rescue therapy would potentially benefit some patients with an expanded treatment in cerebral ischemia score (eTICI) 2b50/2b67 reperfusion but also harbors increased risks. The relative benefits of eTICI 2c/3 over eTICI 2b50/67 in clinically important subpopulations were analyzed. METHODS: Retrospective analysis of our institutional database for all patients with occlusion of the intracranial internal carotid artery (ICA) or the M1/M2 segment undergoing MT and final reperfusion of ≥eTICI 2b50 (903 patients). The heterogeneity in subgroups of different time metrics, age, National Institutes of Health Stroke Scale (NIHSS), number of retrieval attempts, Alberta Stroke Programme Early CT Score (ASPECTS) and site of occlusion using interaction terms (p(i)) was analyzed. RESULTS: The presence of eTICI 2c/3 was associated with better outcomes in most subgroups. Time metrics showed no interaction of eTICI 2c/3 over eTICI 2b50/2b67 and clinical outcomes (onset to reperfusion p(i) = 0.77, puncture to reperfusion p(i) = 0.65, onset to puncture p(i) = 0.63). An eTICI 2c/3 had less consistent association with mRS ≤2 in older patients (>82 years, p(i) = 0.038) and patients with either lower NIHSS (≤9) or very high NIHSS (>19, p(i) = 0.01). Regarding occlusion sites, the beneficial effect of eTICI 2c/3 was absent for occlusions in the M2 segments (aOR 0.73, 95% confidence interval [CI] 0.33–1.59, p(i) = 0.018). CONCLUSION: Beneficial effect of eTICI 2c/3 over eTICI 2b50/2b67 only decreased in older patients, M2-occlusions and patients with either low or very high NIHSS. Improving eTICI 2b50/2b67 to eTICI 2c/3 in those subgroups may be more often futile. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00062-021-01131-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2022-01-06 2022 /pmc/articles/PMC9424153/ /pubmed/34989817 http://dx.doi.org/10.1007/s00062-021-01131-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Kurmann, Christoph C. Mujanovic, Adnan Piechowiak, Eike I. Dobrocky, Tomas Zibold, Felix Beyeler, Morin Vynckier, Jan Seiffge, David Meinel, Thomas R. Mordasini, Pasquale Arnold, Marcel Fischer, Urs Gralla, Jan Kaesmacher, Johannes Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit? |
title | Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit? |
title_full | Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit? |
title_fullStr | Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit? |
title_full_unstemmed | Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit? |
title_short | Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67: Are there Patients who are less Likely to Benefit? |
title_sort | heterogeneity of the relative benefits of tici 2c/3 over tici 2b50/2b67: are there patients who are less likely to benefit? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424153/ https://www.ncbi.nlm.nih.gov/pubmed/34989817 http://dx.doi.org/10.1007/s00062-021-01131-0 |
work_keys_str_mv | AT kurmannchristophc heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT mujanovicadnan heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT piechowiakeikei heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT dobrockytomas heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT ziboldfelix heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT beyelermorin heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT vynckierjan heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT seiffgedavid heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT meinelthomasr heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT mordasinipasquale heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT arnoldmarcel heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT fischerurs heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT grallajan heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit AT kaesmacherjohannes heterogeneityoftherelativebenefitsoftici2c3overtici2b502b67aretherepatientswhoarelesslikelytobenefit |